目的 探讨补肺活血胶囊联合布地奈德福莫特罗粉吸入剂治疗慢性阻塞性肺疾病急性加重期的临床疗效。方法 选取2015年10月-2018年10月解放军第一医院收治的96例慢性阻塞性肺疾病急性加重期患者为研究对象，将所有患者随机分为对照组和治疗组，每组各48例。对照组患者吸入布地奈德福莫特罗粉吸入剂，2吸/次，2次/d。治疗组在对照组基础上口服补肺活血胶囊，4粒/次，3次/d。两组患者持续治疗1个月。观察两组的临床疗效，比较两组的临床症状改善时间、肺功能指标、血气指标水平、血清炎性因子水平。结果 治疗后，对照组和治疗组的总有效率分别为83.33%、95.83%，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组患者喘息、咳嗽、哮鸣音消失时间显著短于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者一秒用力呼气容积（FEV1）、用力肺活量（FVC）和FEV1/FVC均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组患者肺功能指标明显高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者动脉血二氧化碳分压（pCO₂）水平显著降低，血氧分压（pO₂）水平显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组血气指标水平显著高于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、白细胞介素-8（IL-8）水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组血清炎性因子水平明显低于对照组，两组比较差异有统计学意义（P<0.05）。结论 补肺活血胶囊联合布地奈德福莫特罗粉吸入剂治疗慢性阻塞性肺疾病急性加重期具有较好的临床疗效，可改善患者肺功能和临床症状，降低炎性因子水平，具有一定的临床推广应用价值。

Objective To investigate the efficacy of Bufei Huoxue Capsules combined with Budesonide and Formoterol Fumarate Powder for inhalation in treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods Patients (96 cases) with acute exacerbation of chronic obstructive pulmonary disease in the First Hospital of PLA from October 2015 to October 2018 were randomly divided into control and treatment groups, and each group had 48 cases. Patients in the control group were inhalation administered with Budesonide and Formoterol Fumarate Powder for inhalation, 2 inhalations/time, twice daily. Patients in the treatment group were po administered with Bufei Huoxue Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and clinical symptoms improvement time, pulmonary function indexes, blood gas indexes, and serum levels of inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.33% and 95.83%, respectively, and there was difference between two groups (P<0.05). After treatment, the disappearance times of wheezing, coughing, and wheezing in the treatment group were significantly shorter than those in the control group, with significant difference between two groups (P<0.05). After treatment, FEV1, FVC, and FEV1/FVC in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the pulmonary function indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of pCO₂ in two groups were significantly decreased, but the levels of pO₂ in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the blood gas indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of TNF-α, IL-6, and IL-8 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And serum levels of inflammatory factors s in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Bufei Huoxue Capsules combined with Budesonide and Formoterol Fumarate Powder for inhalation has clinical curative effect in treatment of acute exacerbation of chronic obstructive pulmonary disease, can improve the pulmonary function and clinical symptoms of patients, and reduce the level of inflammatory factors, which has a certain clinical application value.